ARTICLE | Clinical News
Evacetrapib: Phase III ongoing
September 28, 2015 7:00 AM UTC
Eli Lilly said a DMC recommended continuation of the double-blind, placebo-controlled, international Phase III ACCELERATE trial evaluating 130 mg oral evacetrapib once daily for <=4 years in 12,095 pa...